A long story made too short: Surrogate variables and the communication of HPV vaccine trial results

Journal of Epidemiology and Community Health

Volumn 64, Issue 5, 2010, Pages 377-378

  Gerhardus, Ansgar ^a   Razum, Oliver ^a  

^a BIELEFELD UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

EDITORIAL; EPIDEMIOLOGY; FEMALE; HUMAN; PAPILLOMAVIRUS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARD; TREATMENT OUTCOME;

EPIDEMIOLOGIC RESEARCH DESIGN; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

HUMAN PAPILLOMAVIRUS;

EID: 77952062360     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech.2009.090183     Document Type: Editorial

References (13)

1. Svensson S. Healthy skepticism members. A collection of misleading surrogate end points. 2009. http://www.healthyskepticism.org/news/2009/ Apr09.pdf (accessed 7 Aug 2009).
2. Taylor RS, Elston J. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports. Health Technol Assess 2009;13:8.
3. Lippman A. Human papillomavirus (HPV) vaccination and the development of public policies [Editorial]. J Epidemiol Community Health 2008; 62:570-571 (Pubitemid 351960214)
4. Porta M, Gonzalez López-Valcárcel B, Márquez Calderón S, et al. Doubts on the appropriateness of universal human papillomavirus vaccination: is evidence on public health benefits already available? J Epidemiol Community Health 2008;62:667.
5. Porta M. The improbable plunge. What facts refute reasons to expect that the effectiveness of HPV vaccination programs to prevent cervical cancer could be low? [Editorial]. Prev Med 2009;48:407-410
6. Daren M. Assessing the effectiveness of human papillomavirus (HPV) vaccination to prevent cervical cancer: perspectives from Germany. J Epidemiol Community Health 2010;64:103-104
7. EMEA. Assessment Report for Gardasil. 2008. No: EMEA/H/C/000703/II/0013. http://www.emea. europa.eu/humandocs/PDFs/EPAR/gardasil/GardasilH-703-II-13-AR. pdf (accessed 7 Aug 2009).
8. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927 (Pubitemid 46740302)
9. FDA. Vaccines and Related Biological Products Advisory Committee (VRBPAC). Gardasil™ HPV Quadrivalent Vaccine. May 18, 2006. VRBPAC MeetingBackground Document. http://www.fda.gov/ ohrms/dockets/ac/06/briefing/ 2006-4222B3.pdf (accessed 7 Aug 2009).
10. Sanofi Pasteur MSD. Press release from 10.5.2007. [Original in German. Translation by the authors]. www.ots.at/anhang/OTS-20070510-0TS0106-id25772057. pdf (accessed 7 Aug 2009).
11. Ständige Impfkommission (STIKO) am Robert Koch-Institut. Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren -Empfehlung und Begründung. Epidemiol Bull 2007:97-103.
12. The Swedish Council on Technology Assessment in Health Care. General childhood vaccination against HPV 16 and 18 aimed at preventing cervical cancer. SBU alert report No 2008-2101, Stockholm. 2008. www.sbu.se/ upload/Publikationer/Content0/3/General-Childhood-Vaccination-HPV-16-18- Preventing-Cervical-Cancer-200801.pdf.
13. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14. doi: 10.1016/ S0140-6736(09)61248-61254 [published Online First: 6 July 2009].